# **Study population counts**

## Counts by exposure cohort

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Acute myocardial infarction | Users of abiraterone + prednisone with CRPC (n = 4,118) | MDCR | 1,602 | 38.9 |
| Optum | 2,516 | 61.1 |
| Users of enzalutamide with CRPC (n = 5,435) | MDCR | 2,342 | 43.09 |
| Optum | 3,093 | 56.91 |
| Alzheimers/dementia/cognative decline | Users of abiraterone + prednisone with CRPC (n = 3,879) | MDCR | 1,532 | 39.49 |
| Optum | 2,347 | 60.51 |
| Users of enzalutamide with CRPC (n = 5,089) | MDCR | 2,208 | 43.39 |
| Optum | 2,881 | 56.61 |
| Cardiovascular morbidity (composite) | Users of abiraterone + prednisone with CRPC (n = 3,568) | MDCR | 1,389 | 38.93 |
| Optum | 2,179 | 61.07 |
| Users of enzalutamide with CRPC (n = 4,642) | MDCR | 1,974 | 42.52 |
| Optum | 2,668 | 57.48 |
| Heart failure | Users of abiraterone + prednisone with CRPC (n = 3,827) | MDCR | 1,505 | 39.33 |
| Optum | 2,322 | 60.67 |
| Users of enzalutamide with CRPC (n = 4,968) | MDCR | 2,141 | 43.1 |
| Optum | 2,827 | 56.9 |
| Hemorrhagic stroke | Users of abiraterone + prednisone with CRPC (n = 4,306) | MDCR | 1,702 | 39.53 |
| Optum | 2,604 | 60.47 |
| Users of enzalutamide with CRPC (n = 5,670) | MDCR | 2,454 | 43.28 |
| Optum | 3,216 | 56.72 |
| Ischemic stroke | Users of abiraterone + prednisone with CRPC (n = 4,145) | MDCR | 1,635 | 39.45 |
| Optum | 2,510 | 60.55 |
| Users of enzalutamide with CRPC (n = 5,497) | MDCR | 2,376 | 43.22 |
| Optum | 3,121 | 56.78 |
| Sudden cardiac death | Users of abiraterone + prednisone with CRPC (n = 4,316) | MDCR | 1,710 | 39.62 |
| Optum | 2,606 | 60.38 |
| Users of enzalutamide with CRPC (n = 5,692) | MDCR | 2,467 | 43.34 |
| Optum | 3,225 | 56.66 |

## Counts by database

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Acute myocardial infarction | MDCR (n = 3,944) | Users of abiraterone + prednisone with CRPC | 1,602 | 40.62 |
| Users of enzalutamide with CRPC | 2,342 | 59.38 |
| Optum (n = 5,609) | Users of abiraterone + prednisone with CRPC | 2,516 | 44.86 |
| Users of enzalutamide with CRPC | 3,093 | 55.14 |
| Alzheimers/dementia/cognative decline | MDCR (n = 3,740) | Users of abiraterone + prednisone with CRPC | 1,532 | 40.96 |
| Users of enzalutamide with CRPC | 2,208 | 59.04 |
| Optum (n = 5,228) | Users of abiraterone + prednisone with CRPC | 2,347 | 44.89 |
| Users of enzalutamide with CRPC | 2,881 | 55.11 |
| Cardiovascular morbidity (composite) | MDCR (n = 3,363) | Users of abiraterone + prednisone with CRPC | 1,389 | 41.3 |
| Users of enzalutamide with CRPC | 1,974 | 58.7 |
| Optum (n = 4,847) | Users of abiraterone + prednisone with CRPC | 2,179 | 44.96 |
| Users of enzalutamide with CRPC | 2,668 | 55.04 |
| Heart failure | MDCR (n = 3,646) | Users of abiraterone + prednisone with CRPC | 1,505 | 41.28 |
| Users of enzalutamide with CRPC | 2,141 | 58.72 |
| Optum (n = 5,149) | Users of abiraterone + prednisone with CRPC | 2,322 | 45.1 |
| Users of enzalutamide with CRPC | 2,827 | 54.9 |
| Hemorrhagic stroke | MDCR (n = 4,156) | Users of abiraterone + prednisone with CRPC | 1,702 | 40.95 |
| Users of enzalutamide with CRPC | 2,454 | 59.05 |
| Optum (n = 5,820) | Users of abiraterone + prednisone with CRPC | 2,604 | 44.74 |
| Users of enzalutamide with CRPC | 3,216 | 55.26 |
| Ischemic stroke | MDCR (n = 4,011) | Users of abiraterone + prednisone with CRPC | 1,635 | 40.76 |
| Users of enzalutamide with CRPC | 2,376 | 59.24 |
| Optum (n = 5,631) | Users of abiraterone + prednisone with CRPC | 2,510 | 44.57 |
| Users of enzalutamide with CRPC | 3,121 | 55.43 |
| Sudden cardiac death | MDCR (n = 4,177) | Users of abiraterone + prednisone with CRPC | 1,710 | 40.94 |
| Users of enzalutamide with CRPC | 2,467 | 59.06 |
| Optum (n = 5,831) | Users of abiraterone + prednisone with CRPC | 2,606 | 44.69 |
| Users of enzalutamide with CRPC | 3,225 | 55.31 |